Table 5.

The observed sequence changes and the corresponding amino acid substitutions in KRAS c12/13 and c59/61 in the study population

KRAS c12/13 and c59/61 sequence change	Amino acid change	Serrated adenocarcinomas, N (%)	Non-serrated adenocarcinomas, N (%)	Total, N (%)	P-value (Fisher's exact test)	Serrated adenomas	Non-serrated adenomas	Total	P-value (Fisher's exact test)
c12 GGT→GTT	Gly→Val	4 (21.1)	7 (43.8)	11 (31.4)	0.047	4 (36.4)	0 (0)	4 (33.3)	1.00
c12 GGT→TGT	Gly→Cys	1 (5.3)	3 (18.8)	4 (11.4)		0 (0)	0 (0)	0 (0)
c12 GGT→GAT	Gly→Asp	10 (52.6)	2 (12.5)	12 (34.3)		4 (36.4)	1 (100)	5 (41.7)
c13 GGC→GAC	Gly→Asp	2 (10.5)	3 (18.8)	5 (14.3)		1 (9.1)	0 (0)	1 (8.3)
c59 GCA→GGA	Ala→Gly	0 (0)	1 (6.3)	1 (2.9)		0 (0)	0 (0)	0 (0)
c61 CAA→AAA	Gln→Lys	2 (10.5)	0 (0)	2 (5.7)		2 (18.2)	0 (0)	2 (16.7)
Total		19 (100)	16 (100)	35 (100)		11 (100)	1 (100)	12 (100)